About Harry Rowland
Harry Rowland is VahatiCor’s chief executive officer. He leads its work on interventional treatments for people with coronary microvascular dysfunction.
Rowland previously co-founded Endotronix and served as its chief executive officer and president. He guided the Cordella Pulmonary Artery Sensor and Heart Failure System into commercial use. Under his leadership, Endotronix raised more than $150 million and grew beyond 150 employees. He oversaw the PROACTIVE-HF trial as Cordella advanced to FDA premarket approval and commercial launch. After Edwards Lifesciences acquired Endotronix in 2024, he stayed to support national coverage and European regulatory milestones. He holds two mechanical engineering degrees, including a doctorate from Georgia Institute of Technology. He also serves as a VahatiCor director.
Experience
This experience comes from official bios and from SEC filings. For roles taken from filings, the years are when the filings name Harry Rowland in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people Harry Rowland works with at each company, as listed on that company's latest Form D.
